Recent peptide news, launches, updates, and notable developments with enough context to understand why they matter.
3 news
FDA has set a July 23, 2026 compounding committee review for BPC-157, TB-500, and KPV, giving these recovery peptides a concrete U.S. regulatory date. It is not approval, but it is a real access milestone.
New April 2026 prescribing data shows how Vyleesi and Addyi are reaching similar specialists through very different access routes—a gap that could shape your options.
MOTS-c has finally entered human efficacy testing in the exact metabolic scenario that drove years of interest. A recruiting Phase 2a trial means the peptide's metabolism story is now being proven in real people, not just lab research.